Adverse Events in CAR T-Cell Therapies: Joseph A. Fraietta, PhD

Video

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed safety concerns with CAR T-cell therapies.

“I think we're going to be able to touch solid tumor indications in the very near future. The outlook is really bright...I think CAR T cells are going to become a staple in immunooncology and modern medicine and hopefully, offer curative treatment options for patients with these refractory malignancies.”

While chimeric antigen receptor (CAR) T-cell therapy has the potential to cure many previously incurable diseases, T-cell exhaustion remains a barrier to eliciting deep and durable responses in some patients. Researchers from the University of Pennsylvania’s Perelman School of Medicine, including Joseph A. Fraietta, PhD, found that JQ1, a small-molecule inhibitor currently used to treat a variety of cancers, “reinvigorates” patient T cells and thus can address the issue of exhausted T cells.

GeneTherapyLive spoke with Fraietta, who is an assistant professor of microbiology and director of the Solid Tumor Immunotherapy Lab at the Center for Advanced Cellular Therapies, about his findings as well as his work with CAR T-cell therapies in general. He discussed adverse events seen with the use of CAR T-cell therapies, including cytokine release syndrome and neurotoxicity, and improvements in clinical management strategies.

Despite recent safety concerns, Fraietta’s outlook on CAR T-cell therapies remains positive, he said, stating that CAR T-cell therapies are the future for both hematologic malignancies and solid tumors.

REFERENCES
Existing drug may help improve responses to cellular therapies in advanced leukemias. News release. University of Pennsylvania. August 16, 2021. https://www.pennmedicine.org/news/news-releases/2021/august/existing-drug-may-help-improve-responses-to-cellular-therapies-in-advanced-leukemias
Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.